Precision Ethics

•

0 likes•143 views

Input speech to panel on ethics from Nicoletta Iacobacci at the DayOne Conference Shaping the future of Health September 9th 2019

More from DayOne

Expert Event Legal challenges and opportunities for digital health innovation

DayOne

Introduction by Thomas Brenzikofer, DayOne, Basel Area Business & Innovation Greenfield or jungle? Navigating the legal landscape for digital healthcare innovation At first sight, it’s hard not to agree that dealing with the legal aspects of creating healthcare innovation is — although necessary — a rather unsexy topic. So it comes as no surprise that the DayOne Experts Event “Legal challenges and opportunities for healthcare innovation”, held online on September 30, attracted a slightly smaller audience than when the talks usually concern revolutionary new pieces of digital technology ready to disrupt healthcare as we know it — for the better.

Future of aging day one 20200630 zaynakhayat

DayOne

This document discusses the future of aging and outlines several shifts that are expected to occur. It summarizes a book on the topic that explores how aging is transforming in areas like identity, community, health interventions, and technology. The document presents examples of emerging trends like reframing what it means to age, new models for aging communities, a shift from treating illness to empowering health, and technologies that can enhance independence and quality of life for older adults.

Value-based Healthcare - Towards a systems approach in chronic diseasesn

DayOne

Value-based Healthcare by Lyfegen on Pioneering value & data-driven healthcare

DayOne

Value-based Healthcare today and tomorrow by Deloitte.

DayOne

VBHC today and tomorrow There is an increasing need for a value-based healthcare model based on holistic patient and health system outcomes, which can only be achieved through genuine collaboration between stakeholders. Value-based contracts require defining appropriate outcome measures, collecting and analyzing real-world data, and addressing challenges such as misaligned incentives among payers, providers, and pharmaceutical companies. The COVID-19 pandemic is likely to accelerate trends in healthcare such as greater emphasis on value-based care, data analytics, technology innovation, and patient engagement. Post-COVID, there are opportunities for life sciences companies to strengthen evidence of value, support health system capacity and digital adoption, and engage differently with regulators and payers.

DayOne Experts - Value Based Healthcare

DayOne

This document discusses value-based healthcare and consists of presentations from a DayOne Experts event on June 18, 2020. It explores why value-based healthcare is needed, how it is implemented, and who benefits from it. The event included breakout sessions on how COVID-19 could catalyze value-based approaches, how it may change disease treatment and research, its potential to trigger innovation and new business models, and how to define and measure healthcare value from the patient perspective.

Aging Well project - Workshop 1 mobility

DayOne

The Aging Well Catalyst Project would involve a series of 5 workshops bringing together stakeholders from areas like healthcare, technology, and senior care to identify innovation opportunities for an aging society. The outputs would be published in a series of white papers and culminate in a public event. The Aging Well Accelerator would select and accelerate the top 3 startups in technologies supporting healthy aging over 6 months to help their path to market. Both projects aim to drive innovation and collaboration around aging well.

Expert Event DayOneBasel on Mental Health

DayOne

20191203 DOE Data Driven Healthcare- Expert Event

DayOne

This document summarizes a presentation on data-driven healthcare given at the DayOne Experts conference in Basel on December 3rd, 2019. The presentation discusses whether the healthcare system is ready for data-driven approaches and what is needed to enable new data-driven health solutions. It notes that while digitalization in Swiss medical practices is increasing, coordination between different parts of the treatment chain remains a challenge. The Swiss Personalized Health Network aims to connect different health data sources and establish national infrastructure to enable interoperable exchange of health data for research purposes. University hospitals are working to structure, standardize and integrate different types of clinical and research data according to SPHN requirements.

Healthcare delivery in the periphery workshop output

DayOne

This document summarizes a tri-national workshop on healthcare delivery in peripheral regions. The workshop brought together participants from Germany, France, and Switzerland to identify challenges in peripheral healthcare, develop collaborative projects to address these challenges, and plan next steps. Three priority projects were selected: 1) A platform for hospitals to share best practices and develop an adherence app, 2) A workshop on technological solutions to attract physicians to peripheral areas, and 3) An exchange program for nurses and nursing students to collaborate with technology companies and work towards harmonizing training across borders. Immediate next steps included reporting outcomes to relevant conferences and planning an expert workshop in early 2020.

2019.10.30 DayOne Expert Event patient centricity

DayOne

DayOne Accelerator 2019/20 shortlisted projects

DayOne

YouROK delivers a positive emotional health platform to help kids, families and professionals prevent mental health issues and build healthier families. The platform includes an app that builds emotional resilience while measuring deterioration in emotional well-being to proactively offer targeted treatment. Using deep learning to assess emotional health, YouROK keeps parents and professionals informed of a child's mental health status through a dashboard and alerts.

East-West Ethics - The China Perspective

DayOne

This document provides information about Shanghai, China including its population, transportation infrastructure, universities, and healthcare system. It discusses several major hospitals in Shanghai - Renji Hospital, Zhongshan Hospital, and Fudan Cancer Institute. It provides details on the capacity, staffing, and services of each hospital. The document raises questions about ethics, data, privacy, and how to optimize hospitals in China given challenges with lack of universal healthcare, doctor shortages, and hospital overcrowding.

Durrenmatt's Computer Scientists: Caught between moral and technological deve...

DayOne

Insights-MD

DayOne

How start-up funding in digital health can work

DayOne

The document outlines different stages of start-up funding for digital health companies, including idea stage with the founder's own money, co-founder stage with two owners, family and friends investing, seed rounds with business angels, Series A rounds with venture capitalists, and successful IPOs. It notes that most start-ups fail due to running out of money and not engaging with potential investors, experts, regulators, payers, users, and patients who could help. The presentation encourages understanding these stakeholders and what can be done to succeed in obtaining funding.

Asia Pac Healthtech landscape

DayOne

Introduction DayOne conference 2019

DayOne

The DayOne Conference 2019 was held on September 9th at FHNW in Muttenz. The one-day conference focused on shaping the future of health and included panels with patients and industry professionals, sessions on ethics, financing innovation, and a workshop. There were over 450 participants, including 30 projects/entrepreneurs, 40 volunteers, and a keynote from digital health futurist Maneesh Juneja. The conference was organized by the DayOne team and supported various partners to bring together over 1500 healthcare innovators in the Basel area.

Keynote - Shaping the future of Health

DayOne

The document discusses shaping the future of health care and how AI could be used to improve patient care and staff experience. It describes how AI technologies like neural networks are being developed to analyze CCTV footage to predict medical emergencies and alerts first responders. However, care must be taken to avoid discrimination and harm when using these automated models. The document also questions how AI can be used to create a better world and return on investment for health systems.

Day one conference projects with journey maps

DayOne

More from DayOne (20)

Expert Event Legal challenges and opportunities for digital health innovation

Future of aging day one 20200630 zaynakhayat

Value-based Healthcare - Towards a systems approach in chronic diseasesn

Value-based Healthcare by Lyfegen on Pioneering value & data-driven healthcare

Value-based Healthcare today and tomorrow by Deloitte.

DayOne Experts - Value Based Healthcare

Aging Well project - Workshop 1 mobility

Expert Event DayOneBasel on Mental Health

20191203 DOE Data Driven Healthcare- Expert Event

Healthcare delivery in the periphery workshop output

2019.10.30 DayOne Expert Event patient centricity

DayOne Accelerator 2019/20 shortlisted projects

East-West Ethics - The China Perspective

Durrenmatt's Computer Scientists: Caught between moral and technological deve...

Insights-MD

How start-up funding in digital health can work

Asia Pac Healthtech landscape

Introduction DayOne conference 2019

Keynote - Shaping the future of Health

Day one conference projects with journey maps

Recently uploaded

Male Infertility and Investigations

Reenaz Shaik

Abnormal CSF Diagnosis and Lumbar puncture

Preet Mehta

POTENTIAL TARGET DISEASES FOR GENE THERAPY SOURAV.pptx

souravpaul769171

Embyonal Stem Cells - Properties and Classification

Reenaz Shaik

$Immature platelet fraction (IPF)(Reticulated Platelets)$ $Immature platelet fraction (IPF)(Reticulated Platelets)$

Immature platelet fraction (IPF)(Reticulated Platelets)

Reenaz Shaik

Nursing management of patient with peritoneal dialysis

shivalingatalekar1

Hb electrophoresis- Types, Procedure and Analysis

Reenaz Shaik

Introduction to Removable partial dneture.pptx

Shamsuddin Mahmud

Causes Of Tooth Loss PERIODONTAL PROBLEMS ( PERIODONTITIS, GINIGIVITIS) Systemic Causes Of Tooth Loss 1. Diabetes Mellitus 2. Female Sexual Hormones Condition 3. Hyperpituitarism 4. Hyperthyroidism 5. Primary Hyperparathyroidism 6. Osteoporosis 7. Hypophosphatasia 8. Hypophosphatemia Causes Of Tooth Loss CARIES/ TOOTH DECAY Causes Of Tooth Loss CAUSES OF TOOTH LOSS Consequence of tooth loss Anatomic Loss of ridge volume both height and width Bone loss : mandible > maxilla Posteriorly > anteriorly Anatomic consequences Broader mandibular arch with constricting maxilary arch Attached gingiva is replaced with less keratinised oral mucosa which is more readily traumatized. Anatomic consequences Tipping of the adjacent teeth Supraeruption of the teeth Traumatic occlusion Premature occlusal contact Anatomic Consequences Anatomic Consequences Physiologic consequences Physiologic Consequences Decreased lip support Decreased lower facial height Physiologic Consequences Physiologic consequences Education of Patient Diagnosis, Treatment Planning, Design, Treatment, Sequencing, and Mouth Preparation Support for Distal Extension Denture Bases Establishment and Verification of Occlusal Relations and Tooth Arrangements Initial Placement Procedures Periodic Recall Education of Patient Informing a patient about a health matter to secure informed consent. Patient education should begin at the initial contact with the patient and should continue throughout treatment. The dentist and the patient share responsibility for the ultimate success of a removable partial denture. This educational procedure is especially important when the treatment plan and prognosis are discussed with the patient. Diagnosis, Treatment Planning, Design, Treatment, Sequencing, and Mouth Preparation Begin with thorough medical and dental histories. The complete oral examination must include both clinical and radiographic interpretation of: caries the condition of existing restorations periodontal conditions responses of teeth (especially abutment teeth) and residual ridges to previous stress The vitality of remaining teeth Continued….. Occlusal plan evaluation Arch form Evaluation of Occlusal relationship through mounting the diagnostic cast The dental cast surveyor is an absolute necessity in which patients are being treated with removable partial dentures. Mouth preparations, in the appropriate sequence, should be oriented toward the goal of providing adequate support, stability, retention, and a harmonious occlusion for the partial denture. Support for Distal Extension Denture Bases A base made to fit the anatomic ridge form does not provide adequate support under occlusal loading. The base may be made to fit the form of the ridge when under function. Support for Distal Extension Denture Bases This provides support

Accommodation and Convergence measurement and types

PriyanshSharma67

2- MRI Anatomy RMI 317 Brain Anatomy - Part 1 .pdf

mzakradiology1

SNAKE BITE presentation... Ppt..........

kinggameone94

Gene therapy - Types, Advantages and genetic manifestations in molecular med...

Reenaz Shaik

Comfort, Rest, Sleep and Pain.pptx

Nandish Sannaiah

Why Does Seminal Vesiculitis Causes Jelly-like Sperm.pptx

AmandaChou9

SHOCK management and types and ways of diagnosis

Lway1

Mainstreaming #CleanLanguage in healthcare.pptx

Judy Rees

In healthcare, every day, millions of conversations fail. They fail to cover what’s really important, fail to resolve key issues, miss the point and lead to misunderstandings and disagreements. Clean Language is one approach that can improve things. It’s a set of precise questions – and a way of asking them – which help us all get clear on what matters, what we’d like to have happen, and what’s needed. Around 1000 people working in healthcare have trained in Clean Language skills over the past 20+ years. People are using what they’ve learnt, in their own spheres, and share anecdotes of significant successes. But the various local initiatives have not scaled, nor connected with each other, and learning has not been widely shared. This project, which emerged from work done by the NHS England South-West End-Of-Life Network, with help from the Q Community and especially Hesham Abdalla, aims to fix that.

EXPERIMENTAL STUDY DESIGN- RANDOMIZED CONTROLLED TRIAL

Rishank Shahi

Randomized controlled clinical trial is a prospective experimental study. It essentially involves comparing the outcomes in two groups of patients treated with a test treatment and a control treatment, both groups are followed over the same period of time. Prepare a plan of study or protocol a. Define clear objectives b. State the inclusion and exclusion criteria of case c. Determine the sample size, place and period of study d. Design of trial (single blind, double blind and triple blind method) 2. Define study population: Most often the patients are chosen from hospital or from the community. For example, for a study for comparison of home and sanatorium treatment, open cases of tuberculosis may be chosen. 3. Selection of participants by defined criteria as per plan: Selection of participants should be done with precision and should be precisely stated in writing so that it can be replicated by others. For example, out of open cases of tuberculosis those who fulfill criteria for inclusion may be selected (age groups, severity of disease and treatment taken or not, etc.) Randomization ensures that participants have an equal chance to be assigned to one of two or more groups: One group gets the most widely accepted treatment (standard treatment/ gold standard) The other gets the new treatment being tested, which researchers hope and have reason to believe will be better than the standard treatment Subject variation: First, there may be bias on the part of the participants, who may subjectively feel better or report improvement if they knew they were receiving a new form of treatment. Observer bias: The investigator measuring the outcome of a therapeutic trial may be influenced if he knows beforehand the particular procedure or therapy to which the patient has been subjected. Evaluation bias: There may be bias in evaluation - that is, the investigator(Analyzer) may subconsciously give a favorable report of the outcome of the trial. Co-intervention: participants use other therapy or change behavior Study staff, medical providers, family or friends treat participants differently. Biased outcome ascertainment: participants may report symptoms or outcomes differently or physicians Investigators may elicit symptoms or outcomes differently A technique used to prevent selection bias by concealing the allocation sequence from those assigning participants to intervention groups, until the moment of assignment. Allocation concealment prevents researchers from influencing which participants are assigned to a given intervention group. All clinical trials must be approved by Institutional Ethics Committee before initiation It is mandatory to register clinical trials with Clinical Trials Registry of India Informed consent from all study participants is mandatory. A preclinical trial is a stage of research that begins before clinical trials, and during which important feasibility and drug safety data are collected. Following points high.

Exploring Alternatives- Why Laparoscopy Isn't Always Best for Hydrosalpinx.pptx

FFragrant

Hepcidin - Regulation and its role in Iron metabolism

Reenaz Shaik

A comparative study on uroculturome antimicrobial susceptibility in apparentl...

Bhoj Raj Singh

The uroculturome indicates the profile of culturable microbes inhabiting the urinary tract, and it is often required to do a urine culture to find an effective antimicrobial to treat UTIs. This study targeted to understand the profile of culturable pathogens in the urine of apparently healthy (128) and humans with clinical UTIs (161). In urine samples from UTI cases, microbial counts were 1.2×104 ± 6.02×103 colony-forming units (cfu)/ mL, while in urine samples from apparently healthy humans, the average count was 3.33± 1.34×103 cfu/ mL. In eight samples (six from UTI cases and two from apparently healthy people) of urine, Candida (C. albicans 3, C. catenulata 1, C. krusei 1, C. tropicalis 1, C. parapsiplosis 1, C. gulliermondii 1) and Rhizopus species (1) were detected. Candida krusei was detected only in a single urine sample from a healthy person and C. albicans was detected both in urine of healthy and clinical UTI cases. Fungal strains were always detected with one or more types of bacteria. Gram-positive bacteria were more commonly (OR, 1.98; CI99, 1.01-3.87) detected in urine samples of apparently healthy humans, and Gram -ve bacteria (OR, 2.74; CI99, 1.44-5.23) in urines of UTI cases. From urine samples of 161 UTI cases, a total of 90 different types of microbes were detected and, 73 samples had only a single type of bacteria. In contrast, 49, 29, 3, 4, 1, and 2 samples had 2, 3, 4, 5, 6 and 7 types of bacteria, respectively. The most common bacteria detected in urine of UTI cases was Escherichia coli detected in 52 samples, in 20 cases as the single type of bacteria, other 34 types of bacteria were detected in pure form in 53 cases. From 128 urine samples of apparently healthy people, 88 types of microbes were detected either singly or in association with others, from 64 urine samples only a single type of bacteria was detected while 34, 13, 3, 11, 2 and 1 samples yielded 2, 3, 4, 5, 6 and seven types of microbes, respectively. In the urine of apparently healthy humans too, E. coli was the most common bacteria, detected in pure culture from 10 samples followed by Staphylococcus haemolyticus (9), S. intermedius (5), and S. aureus (5), and similar types of bacteria also dominated in cases of mixed occurrence, E. coli was detected in 26, S. aureus in 22 and S. haemolyticus in 19 urine samples, respectively. Gram +ve bacteria isolated from urine samples' irrespective of health status were more often (p, <0.01) resistant than Gram -ve bacteria to ajowan oil, holy basil oil, cinnamaldehyde, and cinnamon oil, but more susceptible to sandalwood oil (p, <0.01). However, for antibiotics, Gram +ve were more often susceptible than Gram -ve bacteria to cephalosporins, doxycycline, and nitrofurantoin. The study concludes that to understand the role of good and bad bacteria in the urinary tract microbiome more targeted studies are needed to discern the isolates at the pathotype level.

Recently uploaded (20)

Male Infertility and Investigations

Abnormal CSF Diagnosis and Lumbar puncture

POTENTIAL TARGET DISEASES FOR GENE THERAPY SOURAV.pptx

Embyonal Stem Cells - Properties and Classification

$Immature platelet fraction (IPF)(Reticulated Platelets)$ $Immature platelet fraction (IPF)(Reticulated Platelets)$

Immature platelet fraction (IPF)(Reticulated Platelets)

Nursing management of patient with peritoneal dialysis

Hb electrophoresis- Types, Procedure and Analysis

Introduction to Removable partial dneture.pptx

Accommodation and Convergence measurement and types

2- MRI Anatomy RMI 317 Brain Anatomy - Part 1 .pdf

SNAKE BITE presentation... Ppt..........

Gene therapy - Types, Advantages and genetic manifestations in molecular med...

Comfort, Rest, Sleep and Pain.pptx

Why Does Seminal Vesiculitis Causes Jelly-like Sperm.pptx

SHOCK management and types and ways of diagnosis

Mainstreaming #CleanLanguage in healthcare.pptx

EXPERIMENTAL STUDY DESIGN- RANDOMIZED CONTROLLED TRIAL

Exploring Alternatives- Why Laparoscopy Isn't Always Best for Hydrosalpinx.pptx

Hepcidin - Regulation and its role in Iron metabolism

A comparative study on uroculturome antimicrobial susceptibility in apparentl...

Precision Ethics

More Related Content

More from DayOne

More from DayOne (20)

Recently uploaded

Recently uploaded (20)